Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Azenosertib is an oral small-molecule inhibitor, making this a direct major product category for the company.
|
$288.28M |
$3.98
-1.36%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
CIA
Citizens, Inc.
Accident & health (A&H) / health insurance offerings are mentioned as part of the product mix.
|
$283.17M |
$5.62
-0.71%
|
|
SY
So-Young International Inc.
So-Young Clinic is a branded network of outpatient aesthetic centers, which is its core revenue driver.
|
$278.99M |
$2.79
-3.79%
|
|
SENS
Senseonics Holdings, Inc.
Senseonics develops and markets implantable medical devices and biometric sensing technologies (Eversense CGM), fitting the Medical Devices & Biometrics investable theme.
|
$274.98M |
$6.75
-1.75%
|
|
HBB
Hamilton Beach Brands Holding Company
Medical devices & biometrics appropriate to HealthBeacon’s connected health offering.
|
$273.03M |
$20.09
-0.40%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$268.51M |
$2.44
-9.61%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$266.57M |
$31.28
-3.01%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$265.65M |
$2.85
-1.04%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$259.13M |
$14.31
-2.39%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$250.60M |
$8.80
-1.07%
|
|
PRE
Prenetics Global Limited
Insighta's FRAGMA liquid biopsy enables multi-cancer early detection.
|
$249.84M |
$17.95
-1.37%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$248.51M |
$0.73
|
|
SNFCA
Security National Financial Corporation
Death care services (cemetery and mortuary) are a direct service offering aligned with healthcare services and facilities.
|
$243.98M |
$9.41
+0.21%
|
|
MGRM
Monogram Orthopaedics, Inc.
Direct product category: Monogram's system is a surgical device used in operating rooms for orthopedic procedures.
|
$243.79M |
$6.00
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$242.48M |
$4.90
+1.03%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy is an implantable cardiac stimulation-based treatment for hypertension, aligning with Cardiology Devices.
|
$238.85M |
$4.23
-2.76%
|
|
ANL
Adlai Nortye Ltd.
Adlai Nortye is a clinical-stage biotechnology company focused on oncology therapies, establishing Biotech - Oncology as its core domain.
|
$238.14M |
$6.53
-3.26%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$237.33M |
$3.96
-4.23%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$235.82M |
$3.31
-5.01%
|
|
SPOK
Spok Holdings, Inc.
GenA alphanumeric pager represents a medical device hardware line under Medical Devices & Biometrics.
|
$231.52M |
$11.24
-2.05%
|
|
SMTI
Sanara MedTech Inc.
bone fusion/orthopedic implants (BiFORM, ALLOCYTE Plus) and associated bone void filler (OsStic) place the company in Orthopedic Devices.
|
$230.66M |
$25.48
-1.66%
|
|
RCMT
RCM Technologies, Inc.
RCMT's offerings align with Healthcare Services & Facilities through its healthcare staffing/model and service delivery to care institutions.
|
$230.24M |
$30.95
+0.52%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$229.22M |
$0.37
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$229.07M |
$4.12
-2.48%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$226.68M |
$3.17
-0.63%
|
|
QNCX
Quince Therapeutics, Inc.
Lead asset targets Ataxia-Telangiectasia, a rare disease, aligning Quince with the Rare Diseases biotech investment theme.
|
$226.67M |
$4.28
-2.73%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$226.34M |
$4.52
-1.74%
|
|
MPAA
Motorcar Parts of America, Inc.
MPAA markets and sells diagnostic equipment, such as the JBT-1 Bench Top tester.
|
$224.72M |
$11.52
-1.96%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$224.70M |
$4.25
-2.64%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$224.12M |
$4.21
-1.06%
|
Showing page 21 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
